A new study that demonstrates the Pfizer vaccine's effectiveness for at least 6 months and it's protection against the South Africa variant has it well-positioned to progress toward licensure. 

"I think (licensure) will give the company some solace that they're not going to be victims of their own success," said Professor Jacob Sherkow. "If you have a very effective vaccine and the vaccine ends the pandemic, then you've ended the emergency that authorized the EUA and you're not authorized anymore. The (biologics license) guarantees that you get to stay on the market indefinitely."

Read the full article at usatoday.com.